In the obese trial cohort, 1 mg moved 24-hour heart rate by +0.7 bpm in the first week, essentially placebo. In a healthy lean Phase 1b group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Brain and Cognitive Health BPC-157 is evidenced to have neuroprotective properties, attenuating damage due to strokes and central nervous system injuries while balancing neurotransmitters to combat symptoms of depression, Parkinsons disease, and schizophrenia [2, 11, 34]
That being said, over the next 5 years, the idea that technology firms may be collecting / utilizing more home energy data than utilities is a possibility
Claims with future dates are rejected immediately